pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,064 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT801Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • Mail-order abortion pills are legal (for now)
    Africa CDC declares Ebola outbreak in DRC, the violent fallout from Trump’s cuts to foreign aid, and more health news
    STAT · 2mo ago↗ source
  • India’s pharma industry is going global. But can it catch up to China?
    A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.
    BioPharma Dive · 2mo ago↗ source
  • Opinion: I’m 73. I wish my pills wouldn’t keep changing colors and shapes
    Pharmaceutical companies, generic manufacturers, and pharmacists should be more careful about changing how pills look.
    STAT · 2mo ago↗ source
← prev
page 31 of 43
next →
20
fda recalls20
fda medwatch16
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Why isn’t alcohol seen as a public health emergency?
    Why isn't alcohol seen as a public health emergency? Alex Hogan talks to STAT's Isabella Cueto and Lev Facher about their new series on this week's STATus Report.
    STAT · 2mo ago↗ source
  • Opinion: Tributes to Craig Venter and the genomics race are missing something important
    A race, two rivals, a photo finish? Former National Human Genome Research Institute archivist explains what Craig Venter tributes are missing.
    STAT · 2mo ago↗ source
  • STAT+: Top U.S. officials pressured Germany to pay more for prescription drugs
    It's a key piece of Trump's effort to secure lower drug prices for U.S. patients.
    STAT · 2mo ago↗ source
  • DOJ accuses Yale and UCLA medical schools of discriminating against white and Asian applicants
    The Justice Department sent a letter to Yale School of Medicine on Thursday, alleging it was illegally discriminating against applicants who are not Black or Hispanic.
    STAT · 2mo ago↗ source
  • PSA screening for prostate cancer reduces disease-specific deaths, new review shows
    Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review
    STAT · 2mo ago↗ source
  • Supreme Court preserves access to widely used abortion pill, while lawsuit plays out
    The Supreme Court on Thursday preserved women’s access to the abortion drug mifepristone, rejecting lower-court restrictions while a lawsuit continues.
    STAT · 2mo ago↗ source
  • Makary’s departure and Cassidy’s tenuous Senate seat
    This week's episode of “The Readout LOUD” is all about health politics, including Marty Makary's departure as FDA commissioner. Listen now.
    STAT · 2mo ago↗ source
  • STAT investigates the epidemic killing 178,000 Americans a year
    Read Executive Editor Rick Berke's letter to STAT readers on "The Deadliest Drug," a new investigative series into the country's failure to address excessive alcohol use.
    STAT · 2mo ago↗ source
  • STAT+: CDC plans to transfer monkeys to nonprofit’s sanctuary as it seeks to reduce animal testing
    The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas, as the agency seeks to phase out…
    STAT · 2mo ago↗ source
  • STAT+: The hunt for FDA’s next leader
    Marty Makary is out, and the Trump administration has a long wish list for its next FDA commissioner.
    STAT · 2mo ago↗ source
  • STAT+: MIT says research has fallen 10%, and grad student enrollment is down
    At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.
    STAT · 2mo ago↗ source
  • Create Medicines raises $122M to bolster in vivo CAR-T therapies
    The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
    BioPharma Dive · 2mo ago↗ source
  • Biogen pushing tau drug forward despite Alzheimer’s study failure
    One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: BeOne wins FDA approval in lymphoma race
    Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • STAT+: Why big digital health players are missing from Medicare’s chronic care experiment
    In this edition of STAT Health Tech: Why big digital health players skipped Medicare's ACCESS pilot, Isomorphic's big raise, and more.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
    Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau
    STAT · 2mo ago↗ source
  • With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
    Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Three years of declining overdose deaths begets cautious optimism and some concerns
    The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
    Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
    STAT · 2mo ago↗ source
  • STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
    CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.
    STAT · 2mo ago↗ source
  • STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
    Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.
    STAT · 2mo ago↗ source
  • STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief
    Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the agency.
    STAT · 2mo ago↗ source